Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS)
- PMID: 36126105
- PMCID: PMC10646852
- DOI: 10.1136/bjo-2021-321005
Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS)
Abstract
Background: Mutations in the L/M cone opsin gene array cause abnormally high perceived retinal contrast and the development of myopia. Environmental factors may also lead to high visual contrast and cause myopia. Diffusion optics technology (DOT) lenses are designed to reduce contrast signalling in the retina and slow myopia progression.
Methods: The Control of Myopia Using Peripheral Diffusion Lenses Efficacy and Safety Study (CYPRESS, NCT03623074) is a 36-month, multicentre, randomised, controlled, double-masked trial evaluating two investigational spectacle lenses versus control lenses in myopic children aged 6-10, with a planned interim analysis at 12 months. The primary endpoints are change from baseline in axial length (AL) and spherical equivalent refraction (SER).
Results: 256 children (58% female; mean age at screening, 8.1 years) were dispensed spectacles. Across all groups, baseline averages were AL 24.02 mm (SD±0.77 mm), SER -2.01 D (SD±0.9 D) using manifest refraction, and SER -1.94 D (SD±1.0 D) using cycloplegic autorefraction. At 12 months, mean difference in SER progression for test 1 versus control was -0.40 D (p<0.0001), representing a 74% reduction and -0.32 D for Test 2 (p<0.0001), representing a 59% reduction. The difference in AL progression for test 1 versus control was 0.15 mm (p<0.0001) and test 2 versus control was 0.10 mm (p=0.0018).
Conclusion: 12-month results from this ongoing trial demonstrate the safety and effectiveness of DOT spectacles for reducing myopic progression.
Keywords: Clinical Trial; Treatment other; Vision.
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: JR is former Chief Medical Officer at SightGlass Vision, and in this role has received meeting and/or travel support, participated in data safety monitoring/advisory boards, and owns stock in the company. CC reports consulting fees from SightGlass Vision and has a pending patent application (17/259,779). GY reports grants from Johnson & Johnson Vision, CooperVision, and Essilor. JN and MN report royalties/licenses, consulting fees and meeting and/or travel support from SightGlass Vision. JN and MN are cofounders and have stock ownership in SightGlass Vision, and are listed as Inventors on patents issued for DOT lens, owned by the University of Washington. TC reports consulting fees, meeting and/or travel support, patents and stock ownership in his role as employee, officer and board member for SightGlass Vision.
Figures



Similar articles
-
Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS).BMJ Open Ophthalmol. 2024 Oct 9;9(1):e001790. doi: 10.1136/bmjophth-2024-001790. BMJ Open Ophthalmol. 2024. PMID: 39384223 Free PMC article. Clinical Trial.
-
The effect of individualized ocular refraction customized spectacle lenses on myopia control in schoolchildren: A 1-year randomised clinical trial.Ophthalmic Physiol Opt. 2024 Sep;44(6):1279-1289. doi: 10.1111/opo.13354. Epub 2024 Jun 27. Ophthalmic Physiol Opt. 2024. PMID: 38935437 Clinical Trial.
-
Real-world outcomes on myopia management efficacy of diverse segmented defocus optics (DSDO) and defocus incorporated multiple segments (DIMS) spectacle lenses in Chinese children: An initial 12-month prospective clinical study.J Optom. 2025 Jan-Mar;18(1):100533. doi: 10.1016/j.optom.2024.100533. Epub 2025 Jan 11. J Optom. 2025. PMID: 39799796 Free PMC article.
-
Interventions to slow progression of myopia in children.Cochrane Database Syst Rev. 2020 Jan 13;1(1):CD004916. doi: 10.1002/14651858.CD004916.pub4. Cochrane Database Syst Rev. 2020. PMID: 31930781 Free PMC article.
-
[Research updates on a role for retinal contrast in myopia control].Zhonghua Yan Ke Za Zhi. 2023 Jun 11;59(6):488-491. doi: 10.3760/cma.j.cn112142-20230207-00042. Zhonghua Yan Ke Za Zhi. 2023. PMID: 37264581 Review. Chinese.
Cited by
-
Chromatic cues for the sign of defocus in the peripheral retina.Biomed Opt Express. 2024 Aug 8;15(9):5098-5114. doi: 10.1364/BOE.537268. eCollection 2024 Sep 1. Biomed Opt Express. 2024. PMID: 39296412 Free PMC article.
-
Limited bandwidth short-wavelength light produces slowly-developing myopia in tree shrews similar to human juvenile-onset myopia.Vision Res. 2023 Mar;204:108161. doi: 10.1016/j.visres.2022.108161. Epub 2022 Dec 16. Vision Res. 2023. PMID: 36529048 Free PMC article.
-
Advances in optical and pharmacological strategies for myopia correction in children.Am J Transl Res. 2025 Apr 15;17(4):2422-2433. doi: 10.62347/GZUA2622. eCollection 2025. Am J Transl Res. 2025. PMID: 40385000 Free PMC article. Review.
-
The Predictive and Explanatory Power of the Contrast Theory of Myopia.Transl Vis Sci Technol. 2025 Mar 3;14(3):11. doi: 10.1167/tvst.14.3.11. Transl Vis Sci Technol. 2025. PMID: 40067289 Free PMC article. No abstract available.
-
Comparison of optical myopia control interventions: effect on peripheral image quality and vision.Biomed Opt Express. 2023 Jun 6;14(7):3125-3137. doi: 10.1364/BOE.486555. eCollection 2023 Jul 1. Biomed Opt Express. 2023. PMID: 37497498 Free PMC article.
References
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical